- Home
- OXM vs ARQT Comparison
OXM vs ARQT Comparison
Compare OXM & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXM
- ARQT
- Stock Information
- Founded
- OXM 1942
- ARQT 2016
- Country
- OXM United States
- ARQT United States
- Employees
- OXM N/A
- ARQT N/A
- Industry
- OXM Apparel
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- OXM Consumer Discretionary
- ARQT Health Care
- Exchange
- OXM Nasdaq
- ARQT Nasdaq
- Market Cap
- OXM 958.1M
- ARQT 2.0B
- IPO Year
- OXM N/A
- ARQT 2020
- Fundamental
- Price
- OXM $58.97
- ARQT $15.73
- Analyst Decision
- OXM Hold
- ARQT Strong Buy
- Analyst Count
- OXM 5
- ARQT 6
- Target Price
- OXM $66.50
- ARQT $18.80
- AVG Volume (30 Days)
- OXM 549.9K
- ARQT 2.6M
- Earning Date
- OXM 03-27-2025
- ARQT 05-13-2025
- Dividend Yield
- OXM 4.64%
- ARQT N/A
- EPS Growth
- OXM 53.66
- ARQT N/A
- EPS
- OXM 5.87
- ARQT N/A
- Revenue
- OXM $1,516,601,000.00
- ARQT $196,542,000.00
- Revenue This Year
- OXM $3.65
- ARQT $56.60
- Revenue Next Year
- OXM $2.74
- ARQT $43.62
- P/E Ratio
- OXM $10.14
- ARQT N/A
- Revenue Growth
- OXM N/A
- ARQT 229.74
- 52 Week Low
- OXM $53.23
- ARQT $6.99
- 52 Week High
- OXM $111.46
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- OXM 37.90
- ARQT 53.83
- Support Level
- OXM $60.34
- ARQT $16.27
- Resistance Level
- OXM $64.39
- ARQT $17.75
- Average True Range (ATR)
- OXM 3.01
- ARQT 1.14
- MACD
- OXM 0.77
- ARQT -0.03
- Stochastic Oscillator
- OXM 51.39
- ARQT 43.73
About OXM Oxford Industries Inc.
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company generates a majority of its revenue from the Tommy Bahama division.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.